Related Experiment Video

Updated: Jul 16, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Sipuleucel-T shows partial advantage in prostate cancer

Paula Gould

    The Lancet. Oncology
    |September 19, 2006
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Related Experiment Videos

    Last Updated: Jul 16, 2026

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
    06:54

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

    Published on: September 3, 2013

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet. Oncology·2026

    Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

    The Lancet. Oncology·2026

    Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

    The Lancet. Oncology·2026

    Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

    The Lancet. Oncology·2026

    A new species of <i>Xylopia</i> (Annonaceae) from the Amazon Basin, with a review of trunciflorous cauliflory in the genus.

    PhytoKeys·2026

    Genomic and Functional Characterization of Sunflower Endophytes Reveals Mechanisms of Drought Tolerance and Growth Promotion.

    Plant direct·2026

    Novel fungal species associated with <i>Arundo donax</i> (Poales, Poaceae) in Jiangxi, China.

    MycoKeys·2026

    Plant growth promotion of rice (<i>Oryza sativa</i> L.) with root endophytic bacteria, isolated from wild Solanaceous medicinal plants <i>Solanum nigrum</i> L., <i>Solanum sisymbriifolium</i> Lam., and <i>Solanum virginianum</i> L.

    3 Biotech·2026

    Elevation shapes the seed endophytic bacteria richness and composition of <i>Taraxacum officinale</i>.

    AIMS microbiology·2026

    SmNAC36 promotes the biosynthesis of bioactive compounds and drought tolerance in Salvia miltiorrhiza.

    Plant communications·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us